India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many people to afford these ...

Ongoing trials of the next generation of weight loss drugs are revealing something unexpected: Some patients are losing too ...

Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...